{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-25-000008","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.596730+00:00","generated_at":"2026-05-26T23:02:37.922138+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mineralys reports FY2024 net loss $177.8M; cash $198.2M; pivotal data expected Q1-Q2 2025","bullets":["Net loss for FY2024 was $177.8M vs $71.9M in FY2023; R&D spend $168.6M vs $70.4M.","Cash, equivalents and investments $198.2M as of Dec 31, 2024; expected to fund operations through Q1 2026.","Topline data from pivotal Advance-HTN trial expected March 2025; Launch-HTN Phase 3 data in mid first half 2025.","Enrollment in Explore-CKD Phase 2 complete; topline data anticipated Q2 2025.","Initiating Phase 2 trial for lorundrostat in moderate-to-severe OSA and hypertension in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-25-000008","json":"https://secwatch.observer/filing/0001933414-25-000008.json","markdown":"https://secwatch.observer/filing/0001933414-25-000008.md","text":"https://secwatch.observer/filing/0001933414-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000008/0001933414-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000008/mlys-20250212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:02:37.922138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}